Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Josef Thaler
Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Sidedness and TP53 Mutations Impact OS in Anti-Egfr but Not Anti-Vegf Treated mCRC - An Analysis of the KRAS Registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
RAS and BRAF in Metastatic Colorectal Cancer Management
Journal of Gastrointestinal Oncology
Oncology
Gastroenterology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Impact of Primary Tumour Location on Second- Or Later-Line Treatment Outcomes in Patients With RAS Wild-Type Metastatic Colorectal Cancer and in All Lines of Treatment in Patients With RAS Mutations in Four Randomised Panitumumab Studies
Clinical Colorectal Cancer
Oncology
Gastroenterology
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan
JAMA Oncology
Cancer Research
Oncology
Relationship Between Tumour Response and Tumour-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials
Clinical Colorectal Cancer
Oncology
Gastroenterology
A Phase I Study of Intravenous Aflibercept With FOLFIRI in Japanese Patients With Previously Treated Metastatic Colorectal Cancer
Investigational New Drugs
Oncology
Pharmacology
FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer
World Journal of Surgical Oncology
Surgery
Oncology
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
